Albutrix is a specialized protein formulated specifically for people with chronic kidney disease. It is a medical food, not a supplement. Clinically it is classified as a keto acid analog — a category of medical nutrition designed to provide all the essential amino acids the body needs from protein, through a metabolic pathway that produces far less nitrogen waste than standard protein supplements. It gives you what protein gives you, with less waste for the kidneys to clear.
Why Standard Protein Supplements Are Wrong For CKD
When the body processes dietary protein, it produces nitrogen waste — primarily urea, measured in blood tests as BUN (blood urea nitrogen). In CKD, reduced filtration means this nitrogen load contributes directly to hyperfiltration and disease progression. Standard protein supplements — whey, plant protein, amino acid blends — generate the same nitrogen waste as dietary protein. They are not appropriate for CKD patients on a protein-restricted protocol.
Keto acid analogs were developed specifically to solve this problem: provide complete essential amino acid nutrition without the nitrogen burden.
What Makes Albutrix Clinically Distinct
Albutrix is not simply a keto acid analog — it is backed by human clinical data showing it can improve in human patients to improve eGFR and achieve therapeutic BUN levels when used with the Kidneyhood very low protein diet.
- Lowest nitrogen content of any keto acid analog in its category — less than 200 mg nitrogen per daily dose
- Lowest supplemental calcium (S3 and S4) — aligned with NKF guidance, safe for diabetics, no blood sugar spikes
- Highest magnesium content of any keto acid analog — associated with improved survival outcomes in CKD research
- No maltodextrin or high-glycemic fillers
- Stage-specific formulas (S3, S4, S5) precisely matched to current GFR level
- Ships internationally without a prescription — the only KAA with this level of global accessibility
- Manufactured in FDA-registered, lot-tested US facilities
- Protected by US Patent 11,253,496 and EU Patent 3,799,724
Proven In Humans Using Drug-Equivalent Clinical Endpoints
Albutrix is supported by peer-level clinical evidence rather than theoretical benefits. It has been studied in human CKD patients — informed consent, HIPAA-compliant data collection, standard statistical methodology — measuring eGFR, BUN, and creatinine. These are the identical endpoints the FDA requires for kidney disease drug approval. A statistically significant dose-response relationship (p = 0.002) between achieved BUN level and eGFR improvement was identified.
In documented clinical studies: 80% of patients improved eGFR | 92% reduced BUN | 86% lowered creatinine
Selecting Your Formula
FDA Registration
Albutrix is an FDA-registered medical food under 21 U.S.C. 360ee(b)(3) — the Orphan Drug Act. Medical foods are a distinct regulatory category from drugs. Albutrix meets all FDA requirements for medical foods and is manufactured in FDA-registered, lot-tested US facilities.